SALT LAKE CITY, May 07, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the reorganization of its European operations to better align company resources to its domestic opportunities while continuing to serve key biopharma partners and patients outside the United States.

盐湖城，2024年5月7日（环球通讯社）--基因检测和精准医学领域的领导者Myriad Genetics，Inc.（纳斯达克：MYGN）今天宣布重组其欧洲业务，以更好地将公司资源与国内机会结合起来，同时继续为美国以外的关键生物制药合作伙伴和患者提供服务。

As part of the reorganization, Myriad signed a definitive agreement to sell its EndoPredict® business to Eurobio Scientific, a leading French group in in vitro medical diagnostics and life sciences. Myriad will also license Eurobio the right to sell Prolaris in vitro diagnostic kits outside the U.S.

作为重组的一部分，Myriad签署了一份最终协议，将其EndoPredict®业务出售给法国领先的体外医学诊断和生命科学集团Eurobio Scientific。Myriad还将授权Eurobio在美国境外销售Prolaris体外诊断试剂盒。

Myriad will license the rights to continue to produce and sell EndoPredict, as a Laboratory Developed Test (LDT), in the U.S. as part of Precise Oncology Solutions, its comprehensive suite of precision medicine tools for breast, prostate, ovarian, pancreatic, endometrial, and colon cancer. “The change in our international strategy is part of our continued effort to accelerate profitable growth while supporting our biopharma partners in the most efficient manner,” said Paul J.

Myriad将授权继续在美国生产和销售EndoPredict，作为实验室开发的测试（LDT），作为精准肿瘤学解决方案的一部分，其针对乳腺癌、前列腺癌、卵巢癌、胰腺癌、子宫内膜癌和结肠癌的全套精准医学工具。PaulJ。

Diaz, president and CEO of Myriad Genetics. “By divesting the EndoPredict business to Eurobio, we believe EndoPredict and our European teammates will have more opportunities to grow given Eurobio’s strength and presence in the European market. This will also allow Myriad to be in a better position to grow our other global businesses more efficiently through strategic partnerships, including licensing and distribution agreements.” The deal is subject to customary closing conditions, and Myriad expects the transaction to close in the second or third quarter of 2024.

迪亚兹是Myriad Genetics的总裁兼首席执行官。“通过将EndoPredict业务剥离给Eurobio，鉴于Eurobio在欧洲市场的实力和存在，我们相信EndoPredict和我们的欧洲队友将有更多的机会增长。这也将使Myriad能够通过战略合作伙伴关系（包括许可和分销协议）更有效地发展我们的其他全球业务。”该交易受惯例成交条件的约束，Myriad预计该交易将在2024年第二或第三季度完成。

About EndoPredict Breast Cancer Prognostic TestEndoPredict is a prognostic test that predi.

关于EndoPredict乳腺癌预后测试EndoPredict是一种预测预后的测试。